Thromboembolic neurologic events in patients with antiphospholipid-antibody syndrome.
Turazzini
M
M
Giavarina
D
D
Del Colle
R
R
Zamperetti
M
M
Schiavon
R
R
Silvestri
M
M
D000026:Abortion, Habitual / Q000209:etiology; D000328:Adult; D000818:Animals; D017152:Antibodies, Antiphospholipid / Q000276:immunology; D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000150:complications* / Q000276:immunology; D001327:Autoimmune Diseases / Q000150:complications* / Q000276:immunology; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D006801:Humans; D019934:International Normalized Ratio / Q000592:standards; D020766:Intracranial Embolism / Q000209:etiology* / Q000517:prevention & control; D020767:Intracranial Thrombosis / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011994:Recombinant Proteins; D012008:Recurrence; D012306:Risk; D012640:Seizures / Q000209:etiology; D013923:Thromboembolism / Q000209:etiology* / Q000276:immunology; D019851:Thrombophilia / Q000209:etiology* / Q000276:immunology; D013924:Thrombophlebitis / Q000209:etiology; D013925:Thromboplastin; D014859:Warfarin / Q000627:therapeutic use
D017152:Antibodies, Antiphospholipid; D000925:Anticoagulants; D011994:Recombinant Proteins; D014859:Warfarin; D013925:Thromboplastin